Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase II trial non-randomized study to evaluate the objective response rate and
stable disease rate (primary endpoints), progression-free survival, overall survival and
toxicities with the combination of doxorubicin and bortezomib in patients with incurable head
and neck adenoid cystic carcinoma. Also, we plan to collect tumor tissue from previous
diagnostic procedures and baseline blood specimens for future correlative studies.